Patients, physicians, health systems and insurers all stand to gain from the inclusion of Cologuard in the HEDIS measures.
Cologuard's inclusion in the leading quality measures means that Exact Sciences’ patient-friendly, noninvasive colon cancer screening test is now part of value-based healthcare. Healthcare providers can earn quality credit for every patient they screened using Cologuard since it launched in 2014 and moving forward into 2017 and beyond.
The Healthcare Effectiveness Data and Information Set (HEDIS) is a standardized healthcare measurement and reporting method created by the National Committee for Quality Assurance (NCQA) and used by 90% of health plans in America.
The Healthcare Effectiveness Data and Information Set (HEDIS) is ... used by 90% of health plans in America.
The HEDIS quality measures promote evidence-based health care and quality service to patients by assessing the performance of health plans on multiple measures. Colorectal cancer screening compliance and patient satisfaction are two measures that are evaluated to generate an overall quality score.
Cologuard continues to achieve a nearly 70% compliance rate,1 and survey data showed that 88% of patients had a very positive experience2 using Cologuard and engaging Exact Sciences compliance service.
The HEDIS results are distilled into report cards that allow for "apples-to-apples" comparison by employers making decisions on which plans to offer to their employees and by consumers making decisions about which plan to choose.
Insurance plans frequently offer performance and quality-based bonus payments to physicians and/or provider groups for achieving targeted rates of success for specific measures. The health plans' goal is to attain a rating of 4.0 in order to receive a 5% quality bonus payment. This can be accomplished through incremental increases in measures like colon cancer screening and positive customer satisfaction.
Patients, physicians, health systems and insurers will benefit from the inclusion of Cologuard in the HEDIS measures. (Click to tweet)
Patients, physicians, health systems and insurers will benefit from the inclusion of Cologuard in the HEDIS measures. Patients will benefit the most through broader access to an easy-to-use colon cancer screening strategy.
1Cologuard’s patient compliance rate is derived from the number of valid tests reported divided by the number of collection kits shipped to patients during the 12-month period ending 60 days prior to June 30, 2016.
2Exact Sciences Laboratories patient satisfaction survey data is cumulative; n = 2,799